Results A total of 21 745 subjects were ultimately included, with a mean age of (54.0±11.4) years; 17 556 (80.74%) were male and 4 289 (19.26%) were female. GBTM results identified four distinct SBP trajectories, each characterised by its SBP range and pattern of change over follow-up (i.e., stable, declining, or increasing). Among 7 088 subjects maintained stable SBP around 115 mmHg (1 mmHg=0.133 kPa), termed the "normal-high blood pressure decline group"; 11 662 subjects maintained stable SBP around 130 mmHg, termed the "normal-high blood pressure stable group"; 1 710 subjects exhibited a gradual increase from 129 mmHg to approximately 160 mmHg during the trajectory period, termed the "normal high blood pressure ascending cohort"; 1 285 subjects saw their SBP rise to around 158 mmHg before declining below 140 mmHg, termed the "normal high blood pressure ascending-descending cohort". DBP identified four distinct trajectories, each characterised by its DBP range and pattern of change over follow-up (i.e., stable, declining, or increasing). Among 4 856 subjects, DBP remained stable around 75 mmHg, termed the "normal-high blood pressure declining group"; 13 668 subjects exhibited stable DBP around 83 mmHg, termed the "normal-high blood pressure stable group"; 1 640 subjects exhibited a gradual increase in DBP from 82 mmHg to approximately 100 mmHg during the trajectory period, termed the "normal high blood pressure rising group"; 1 581 subjects experienced an increase in SBP to around 98 mmHg before declining below 90 mmHg, termed the "normal high blood pressure rising-falling group". Participants across different SBP trajectory groups were comparable in age, sex, BMI, educational attainment, smoking, alcohol consumption, physical activity, SBP, DBP, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), total cholesterol (TC), fasting blood glucose (FBG), high-sensitivity C-reactive protein, estimated glomerular filtration rate (eGFR), isolated systolic hypertension (ISH), isolated diastolic hypertension (IDH), hypertension, diabetes, antihypertensive medication use, and antidiabetic medication use were compared across different DBP trajectory groups. Differences were statistically significant (P<0.05). Comparisons of age, gender, BMI, educational attainment, smoking, alcohol consumption, salt preference, SBP, DBP, HDL-C, LDL-C, TG, TC, FBG, high-sensitivity C-reactive protein, eGFR, ISH, IDH, hypertension, diabetes mellitus, and antihypertensive medication use showed statistically significant differences (P<0.05). The mean follow-up duration was (9.43±1.94) years, during which 1 429 CVD events occurred (259 MI, 1 170 strokes, and 20 concurrent events). The SBP trajectory subgroups (normal high blood pressure decline, stable, increase, and increase-decline) recorded 274, 794, 191, and 170 new CVD cases respectively. The DBP trajectory groups showed 227, 881, 163, and 158 new CVD cases in the normal-high blood pressure decline, stable, increase, and increase-decline groups respectively. Survival curves depicting cumulative CVD incidence were plotted for study subjects. Log-rank test results indicated statistically significant differences in cumulative CVD incidence between different SBP trajectory groups and DBP trajectory groups (χ2=275.39, 90.69; P<0.001). Using Cox proportional hazards regression models, the hazard ratios (HR) for CVD occurrence across different SBP trajectory groups (95%CI) were calculated, with the normal-high blood pressure decline group serving as the reference. The HR for CVD occurrence in the normal-high blood pressure stable group, normal-high blood pressure increase group, and normal-high blood pressure increase-decrease group were 1.41 (1.22-1.62), 1.92 (1.58-2.33), and 2.24 (1.84-2.74), respectively. The HR (95%CI) for stroke occurrence were 1.46 (1.25-1.71), 2.04 (1.65-2.53) and 2.37 (1.90-2.96), respectively. The HR (95%CI) for MI occurrence were 1.25 (0.92-1.72), 1.42 (0.90-2.23) and 1.81 (1.14-2.86), respectively. Using weighted multivariable Cox proportional hazards regression models unconstrained by the proportional hazards assumption, the aHR (95%CI) for CVD occurrence was calculated with the normal-to-high blood pressure decrease group as the reference. The aHR (95%CI) for CVD occurrence in the normal-to-high blood pressure stable group, the normal-to-high blood pressure increase group, and the normal-to-high blood pressure increase-decrease group were 1.43 (1.12-1.82), 2.59 (1.62-4.13), and 2.11 (1.40-3.17), respectively. The aHR (95%CI) for stroke occurrence were 1.45 (1.11-1.71), 2.95 (1.75-4.97) and 2.34 (1.48-3.71), respectively. The aHR (95%CI) for MI occurrence were 1.34 (0.76-2.34), 1.17 (0.62-2.19) and 1.32 (0.69-2.55), respectively. Stratified analysis indicated that only the SBP trajectory showed a statistically significant interaction with gender and age (Pinteraction<0.05), whereas the DBP trajectory did not exhibit a statistically significant interaction with gender and age (Pinteraction>0.05). In the male cohort, using the SBP trajectory normal-high blood pressure decreasing group as the reference group, the HR (95%CI) for CVD occurrence in the normal-high blood pressure stable group, normal-high blood pressure increasing group, and normal-high blood pressure increasing-decreasing group were 1.42 (1.20-1.67), 1.93 (1.53-2.42), and 2.30 (1.82-2.90), respectively; In the female cohort, using the SBP trajectory normal-high blood pressure decline group as the reference group, the HR (95%CI) for CVD occurrence in the stable, rising, and rising-decline groups were 1.80 (1.14-2.85), 2.91 (1.62-5.21), and 2.79 (1.43-5.43), respectively. Among individuals aged <60 years with prehypertension, using the SBP trajectory prehypertension decline group as reference, the HR (95%CI) for CVD occurrence were 1.48 (1.22-1.78), 2.00 (1.46-2.71), and 3.01 (2.24-4.06), respectively. Among normotensive individuals aged ≥60 years, with the declining SBP trajectory group as reference, CVD HR (95%CI) was 1.35 (1.01-1.79), 1.94 (1.40-2.69), and 1.91 (1.35-2.69), respectively.